Supreme Court rejects Teva's 'skinny label' case
Supreme Court declines to hear Teva Pharmaceuticals' challenge to a $235 million award to GlaxoSmithKline in a patent dispute over a generic heart drug.
Source: beckershospitalreview.com
Stay updated with breaking news from Kinny Labels. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Supreme Court declines to hear Teva Pharmaceuticals' challenge to a $235 million award to GlaxoSmithKline in a patent dispute over a generic heart drug.
Delaware held that plaintiff Amarin Pharma failed to plead facts sufficient to show that Hikma Pharmaceuticals’ carved-out product label and/or public marketing statements induced infringement of Amarin’s patents.
Delaware held that plaintiff Amarin Pharma failed to plead facts sufficient to show that Hikma Pharmaceuticals’ carved-out product label and/or public marketing statements induced infringement of Amarin’s patents.